Soquelitinib (CPI-818)
Relapsed/Refractory T Cell Lymphomas (TCL)
Key Facts
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is focused on developing precisely-targeted medicines for difficult-to-treat cancers and immune diseases, with a core platform centered on ITK inhibition. Founded in 2014, the company has advanced its lead candidate, soquelitinib, through Phase 1 trials and maintains a broader clinical pipeline including ciforadenant and mupadolimab. Led by industry veterans who previously developed Rituxan and Imbruvica, Corvus leverages a biomarker-driven, clinical science approach to increase development success and is publicly traded on NASDAQ.
View full company profileAbout Corvus Pharmaceuticals
Corvus Pharmaceuticals is focused on developing precisely-targeted medicines for difficult-to-treat cancers and immune diseases, with a core platform centered on ITK inhibition. Founded in 2014, the company has advanced its lead candidate, soquelitinib, through Phase 1 trials and maintains a broader clinical pipeline including ciforadenant and mupadolimab. Led by industry veterans who previously developed Rituxan and Imbruvica, Corvus leverages a biomarker-driven, clinical science approach to increase development success and is publicly traded on NASDAQ.
View full company profile